
Ramucirumab is a targeted monoclonal antibody used to treat selected advanced cancers, usually after previous treatment has stopped working or is no longer suitable. It is administered by intravenous infusion and may be used alone or with other cancer medicines.
| Generic Name | Ramucirumab |
| Strength | 500 mg |
| Manufacturer | Eli Lilly and Company |
| Packing | 1 vial |
| Prescribed For | Gastric cancer |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |




| Package | USD | GBP | AUD | NZD | PHP | KRW | RON | HKD | MYR | THB | AED |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Vial(s) Of 50ml | $2,550 | £1,894 | A$3,576 | NZ$4,443 | ₱159,656 | ₩3,441,225 | lei 11,621 | HK$19,995 | RM10,385 | ฿83,309 | د.إ9,365 |
Ramucirumab attaches to vascular endothelial growth factor receptor 2, or VEGFR-2. By blocking this receptor, it prevents tumours from developing new blood vessels. Reducing their blood and nutrient supply can slow cancer growth and spread.
Ramucirumab prices may vary between countries depending on the brand, strength, pack size, pharmacy, insurance coverage, government subsidies, taxes and local healthcare policies. The following resources provide country-specific pricing, reimbursement, regulatory or medicine information.
Disclaimer
This website operates in compliance with applicable pharmaceutical laws. All content and data available on this website are intended solely for informational purposes. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Information provided here is for general awareness and does not replace medical advice. We strongly encourage you to consult a qualified healthcare professional for guidance.